Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 4/20 | 0.77 |
| ▸ | TYMS | P04818 | 3/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.77 |
| ▸ | POLB | P06746 | 1/20 | 0.77 |
| ▸ | GAA | P10253 | 1/20 | 0.77 |
| ▸ | HPGD | P15428 | 1/20 | 0.77 |
| ▸ | TSHR | P16473 | 1/20 | 0.77 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | DHFR | P00374 | 5/20 | 0.55 |
| ▸ | GART | P22102 | 2/20 | 0.51 |
| ▸ | ATIC | P31939 | 1/20 | 0.51 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16150298 | 1.00 | AKR1B1 (0.77) | AKR1B1TYMSKDM4EMEN1ALDH1A1 | |
| SCHEMBL14323639 | 1.00 | AKR1B1 (0.77) | AKR1B1TYMSKDM4EMEN1ALDH1A1 | |
| SCHEMBL30185625 | 1.00 | AKR1B1 (0.77) | AKR1B1TYMSKDM4EMEN1ALDH1A1 | |
| SCHEMBL2273314 | 0.94 | AKR1B1 (0.73) | AKR1B1TYMSKDM4EMEN1ALDH1A1 | |
| SCHEMBL1804092 | 0.94 | TYMS (0.70) | AKR1B1TYMSKDM4EMEN1ALDH1A1 | |
| SCHEMBL17061093 | 0.94 | AKR1B1 (0.73) | AKR1B1TYMSKDM4EMEN1ALDH1A1 | |
| SCHEMBL30174303 | 0.92 | AKR1B1 (0.81) | AKR1B1TYMSKDM4EMEN1ALDH1A1 | |
| SCHEMBL15094347 | 0.92 | AKR1B1 (0.81) | AKR1B1TYMSKDM4EMEN1ALDH1A1 | |
| SCHEMBL28141926 | 0.92 | AKR1B1 (0.77) | AKR1B1TYMSKDM4EMEN1ALDH1A1 | |
| SCHEMBL28226859 | 0.91 | AKR1B1 (0.80) | AKR1B1TYMSKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 911 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122056386-A | Moisture absorption resistant slow release microcapsule powder and preparation method and application thereof | 大连医诺生物股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122030612-A | Shear-resistant slow-release microcapsule powder and preparation method and application thereof | 大连医诺生物股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| US-20260114488-A1 | COMPOSITIONS AND METHODS FOR PROMOTING DEVELOPMENT OF INFANT | BOBBIE BABY INC (US) | 2026-04-30 | — | — | US | claimed |
| US-20260014090-A1 | NANOPARTICLES FOR TARGETED NON-SURGICAL SPAYING AND NEUTERING | UNIV GEORGIA (US) | 2026-01-15 | — | — | US | claimed |
| US-12521354-B2 | Nanoparticles for targeted non-surgical spaying and neutering | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2026-01-13 | — | — | US | claimed |
| US-20250375414-A1 | UROLITHIN COMBINATIONS | AMAZENTIS SA (CH) | 2025-12-11 | — | — | US | claimed |
| US-12491325-B2 | Drug delivery devices and methods for administering substances to a body cavity by heterogenous aerosolization for treatment of binge-eating disorders and/or obesity | APTARGROUP, INC. (US) | 2025-12-09 | — | — | US | claimed |
| EP-4633638-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | Luminous Mind Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| US-20250288532-A1 | NANOPARTICLES FOR TREATING PROSTATE CANCER | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2025-09-18 | — | — | US | claimed |
| US-20120004238-A1 | L-methylfolate treatment for psychiatric or neurologic disorders | QUILLIN ROBERT L (US) | 2012-01-05 | — | — | US | claimed |
| WO-2012003073-A1 | L-METHYLFOLATE TREATMENT FOR PSYCHIATRIC OR NEUROLOGIC DISORDERS | QUILLIN ROBERT L (US) | 2012-01-05 | — | — | WO | claimed |
| WO-2011163301-A1 | METHODS OF TREATING OPTIC DISORDERS | GLOBAL HEALTHCARE FOCUS, LLC (US) | 2011-12-29 | — | — | WO | claimed |
| US-20110319356-A1 | Methods Of Treating Optic Disorders | GLOBAL HEALTHCARE FOCUS, LLC | 2011-12-29 | — | — | US | claimed |
| EP-2382995-A2 | Ligand conjugates of Vinca alkaloids, analogs and derivatives | Endocyte, Inc. (US) | 2011-11-02 | — | — | EP | claimed |
| EP-1501551-B1 | Folate-receptor targeted imaging agents | ENDOCYTE INC (US) | 2009-11-18 | — | — | EP | claimed |
| EP-2107912-A2 | OPHTHALMIC AND CONTACT LENS SOLUTIONS CONTAINING FORMS OF VITAMIN B | FXS Ventures, LLC (US) | 2009-10-14 | — | — | EP | claimed |
| WO-2008086270-A2 | OPHTHALMIC AND CONTACT LENS SOLUTIONS CONTAINING FORMS OF VITAMIN B | FXS VENTURES, LLC (US) | 2008-07-17 | — | — | WO | claimed |
| US-20070104744-A1 | OPHTHALMIC AND CONTACT LENS SOLUTIONS CONTAINING FORMS OF VITAMIN B | FXS VENTURES, LLC | 2007-05-10 | — | — | US | claimed |
| US-20050101605-A1 | Oral liquid formulations of methotrexate | DURAMED PHARMACEUTICALS, INC. | 2005-05-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014090-A1 | NANOPARTICLES FOR TARGETED NON-SURGICAL SPAYING AND NEUTERING | FSHR, GNRHR, LHCGR | AKR1B1 3508/4885TYMS 2294/4885KDM4E 967/4885 |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | CACNG6, MC5R, CRH | AKR1B1 4511/4885TYMS 4818/4885KDM4E 1694/4885 |
| US-20250288532-A1 | NANOPARTICLES FOR TREATING PROSTATE CANCER | FSHR, GNRHR, AR | AKR1B1 2907/4885TYMS 1048/4885KDM4E 1463/4885 |
| US-20250375414-A1 | UROLITHIN COMBINATIONS | AHCY, BHMT, BHMT2 | AKR1B1 2805/4885TYMS 731/4885KDM4E 3360/4885 |
| US-20050101605-A1 | Oral liquid formulations of methotrexate | MTX2, MTX1, DHFR | AKR1B1 736/4885TYMS 17/4885KDM4E 2601/4885 |
| US-20260114488-A1 | COMPOSITIONS AND METHODS FOR PROMOTING DEVELOPMENT OF INFANT | SLC19A1, MTHFD1, MTHFD2 | AKR1B1 4674/4885TYMS 29/4885KDM4E 2633/4885 |
| US-12491325-B2 | Drug delivery devices and methods for administering substances to a body cavity by heterogenous aerosolization for treatment of binge-eating disorders and/or obesity | GCG, VAPA, GABRG2 | AKR1B1 4128/4885TYMS 3711/4885KDM4E 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.